Compound Evidence File
#EC-2026-0765
VIP
Filed under Peptides. The bureau holds 112 laboratory returns for this compound from 38 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
38 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 5 Nov 2025 | 23 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 10 Feb 2026 | 1 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 10.0 | 9.9 | 10.0 | 9 May 2026 | 12 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Feb 2026 | 24 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 2 Dec 2025 | 9 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 10.0 | 10.0 | 27 Feb 2026 | 18 May 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 10.0 | 10.0 | 20 May 2026 | 1 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 17 Apr 2026 | 5 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 3 Nov 2025 | 13 Mar 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 10.0 | 10.0 | 10.0 | 16 Apr 2026 | 5 Jul 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 7 | 9.9 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 9.9 | 4 Jun 2026 | 23 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Apr 2026 | 6 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 15 Mar 2026 | 17 May 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Mar 2026 | 11 Aug 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Jan 2026 | 11 Aug 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 20 Apr 2026 | 7 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 6 Jun 2026 | 14 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Jun 2026 | 9 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 9.9 | 9 Apr 2026 | 21 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 10.0 | 20 Jul 2026 | 4 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 9 Apr 2026 | 3 Jun 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 8.9 | 8.5 | 9.6 | 25 May 2026 | 25 May 2026 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 8.8 | 8.8 | 8.8 | 21 May 2025 | 21 May 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.4 | 7.5 | 9.0 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.3 | 6.7 | 9.5 | 21 May 2026 | 21 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 8.3 | 7.5 | 9.4 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 8.1 | 6.6 | 9.1 | 23 May 2026 | 23 May 2026 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 1 | 8.1 | 8.1 | 8.1 | 21 May 2025 | 21 May 2025 |
| Lux Synth AminosCASE #VI-2026-0700 | X | 1 | 7.7 | 7.7 | 7.7 | 20 Jun 2025 | 20 Jun 2025 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 7.3 | 7.3 | 7.3 | 2 Jul 2025 | 2 Jul 2025 |
| Pura PeptidesCASE #VI-2026-0307 | X | 1 | 7.2 | 7.2 | 7.2 | 20 Jun 2025 | 20 Jun 2025 |
| Simple PeptideCASE #VI-2026-0782 | X | 2 | 6.8 | 6.0 | 7.5 | 13 Feb 2025 | 24 May 2026 |
| Peptide SciencesCASE #VI-2026-0867 | X | 3 | 6.5 | 5.8 | 7.3 | 24 Apr 2025 | 26 Jan 2026 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 5.8 | 5.8 | 5.8 | 8 Jul 2025 | 8 Jul 2025 |
| Alpha-GenCASE #VI-2026-0905 | X | 2 | 4.7 | 3.1 | 6.3 | 3 Jun 2025 | 21 May 2026 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 3.9 | 3.9 | 3.9 | 8 Jul 2025 | 8 Jul 2025 |
Open any subject to view the batch-level evidence for VIP alone.